Back to Search
ALI MALLAT, MD
MD
Surgery Physician
NPI: 1508087826IndividualAccepts Medicare
Specialties, Licenses & Credentials
Surgery PhysicianPrimary
Surgery
Code: 208600000X
4301089640(MI)129879(OH)
Surgical Critical Care Physician
Surgery — Surgical Critical Care
Code: 2086S0102X
4301089640(MI)129879(OH)
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
4301089640(MI)
CMS Specialties
PrimaryGENERAL SURGERY
Additional
CRITICAL CARE (INTENSIVISTS)
Education
OTHER
Class of 2000
Research & Publications (20)
Cigarette smoke exposure: a novel cofactor of NAFLD progression?
PMID 19596475·J Hepatol·2009
7-preclinical
Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis.
PMID 19513120·PLoS One·2009
7-preclinical
Cannabinoid receptors as therapeutic targets in the management of liver diseases.
PMID 19259549·Drug News Perspect·2008
6-review
Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis.
PMID 19195630·Diabetes Metab·2008
8-other
The role of laparoscopy in trauma: a ten-year review of diagnosis and therapeutics.
PMID 19097530·Am Surg·2008
8-other
Liver cirrhosis: intravoxel incoherent motion MR imaging--pilot study.
PMID 19011186·Radiology·2008
8-other
Environmental factors as disease accelerators during chronic hepatitis C.
PMID 18279998·J Hepatol·2008
6-review
Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C.
PMID 18242211·Gastroenterology·2008
4-observational
Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver.
PMID 17975129·Am J Physiol Gastrointest Liver Physiol·2008
6-review
CB2 receptors as new therapeutic targets for liver diseases.
PMID 17952109·Br J Pharmacol·2008
6-review
[The endocannabinoid system as a novel target for the treatment of liver fibrosis].
PMID 17412522·Pathol Biol (Paris)·2008
6-review
[Endocannabinoids: therapeutic perspectives in chronic liver diseases].
PMID 17396081·Gastroenterol Clin Biol·2007
7-preclinical
The sphingosine 1-phosphate receptor S1P2 triggers hepatic wound healing.
PMID 17341687·FASEB J·2007
7-preclinical
Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases.
PMID 17298297·Expert Opin Ther Targets·2007
6-review
Endocannabinoids as novel mediators of liver diseases.
PMID 16751709·J Endocrinol Invest·2006
6-review
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.
PMID 16715087·Nat Med·2006
7-preclinical
Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C.
PMID 15892090·Hepatology·2005
8-other
Antifibrogenic role of the cannabinoid receptor CB2 in the liver.
PMID 15765409·Gastroenterology·2005
7-preclinical
Hepatic fibrosis: molecular mechanisms and drug targets.
PMID 15471534·Annu Rev Pharmacol Toxicol·2005
6-review
Molecular mechanisms regulating the antifibrogenic protein heme-oxygenase-1 in human hepatic myofibroblasts.
PMID 15336443·J Hepatol·2004
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 6000 W CREEK RD, SUITE 10
INDEPENDENCE, OH 44131 - Phone
- (216) 986-1256
Quick Facts
- NPI
- 1508087826
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 5
- Locations
- 1
- Years in Practice
- 26
- Publications
- 20
Are you this provider?
Claim Your Profile